Trial
NCT00003534
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Burzynski Research Institute
Collaborators
—
Condition
Stage IV Prostate Cancer
Intervention
Antineoplaston therapy (Atengenal + Astugenal)
Why stopped
No participants enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-31